fexinidazole has been researched along with Neglected Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bayão, TS; Cupertino, MDC; Gomes, AP; Siqueira-Batista, R | 1 |
| Bahia, MT; Diniz, LF; Gonçalves, KR; Mazzeti, AL; Mota, SLA; Pereira, DE | 1 |
| Burki, T | 1 |
| Maxmen, A | 1 |
| Barrett, MP; Brun, R; Don, R; Jacobs, RT; Wang, MZ | 1 |
1 review(s) available for fexinidazole and Neglected Diseases
| Article | Year |
|---|---|
Development of novel drugs for human African trypanosomiasis.
Topics: Animals; Antiprotozoal Agents; Benzoxazoles; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Haplorhini; Humans; Mice; Neglected Diseases; Nitroimidazoles; Trypanosoma brucei brucei; Trypanosomiasis, African | 2011 |
4 other study(ies) available for fexinidazole and Neglected Diseases
| Article | Year |
|---|---|
Fexinidazole and Human African Trypanosomiasis: good news for this important neglected tropical disease.
Topics: Humans; Neglected Diseases; Nitroimidazoles; Trypanocidal Agents; Trypanosomiasis, African | 2019 |
Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment.
Topics: Animals; Chagas Disease; Drug Therapy, Combination; Female; Humans; Inhibitory Concentration 50; Mice; Neglected Diseases; Nifurtimox; Nitro Compounds; Nitroimidazoles; Real-Time Polymerase Chain Reaction; Sulfones | 2021 |
Recognition for Chagas disease.
Topics: Chagas Disease; Humans; Latin America; Neglected Diseases; Nitroimidazoles; Trypanocidal Agents; Trypanosoma cruzi | 2019 |
Busting the billion-dollar myth: how to slash the cost of drug development.
Topics: Africa; Amodiaquine; Anti-Bacterial Agents; Artemisinins; Benzamides; Boron Compounds; Child; Clinical Trials as Topic; Cooperative Behavior; Developed Countries; Developing Countries; Drug Approval; Drug Combinations; Drug Costs; Drug Discovery; Drug Industry; Drug Repositioning; Drug Resistance, Microbial; Female; Humans; Malaria; Neglected Diseases; Negotiating; Nitroimidazoles; Organizations, Nonprofit; Sample Size; Trypanosomiasis, African; World Health Organization | 2016 |